| AVENTIS PHARMACEUTICALS INC. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120114660 | Antibodies Against LLG Polypeptides of the Triacylglycerol Lipase Family - Lipoprotein Lipase like polypeptides, nucleic acids encoding said polypeptides, antisense sequences, and antibodies to said polypeptides are disclosed. Also disclosed are methods for the preparation of said polypeptides in a recombinant system and for the use of said polypeptides to screen for agonists and or antagonists of said polypeptides. Also disclosed are methods and compositions for the treatment of disorders of lipid metabolism. | 05-10-2012 |
| 20120034188 | Akt Nucleic Acids, Polypeptides, and Uses Thereof - The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis. | 02-09-2012 |
| 20110281793 | Method For Reducing Cardiovascular Morbidity And Mortality In Prediabetic Patients And Patients With Type 2 Diabetes - This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient. | 11-17-2011 |
| 20110263831 | NUCLEAR FACTOR kappaB INDUCING FACTOR - The present invention is directed to nuclear factor κB (NFκB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFκB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NFκB induction in a patient, methods and compositions for lowering NFκB induction in a patient, methods for inhibiting inflammation, and methods for manufacture of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided. | 10-27-2011 |
| 20110251240 | Dosing Regimen of Flavopiridol for Treating Cancer - A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in a patient comprising administering to said patient the dosing regimen of the invention. | 10-13-2011 |
| 20110245471 | NUCLEAR FACTOR kappaB INDUCING FACTOR - The present invention is directed to nuclear factor κB (NFκB)-inducing factor polypeptides (NFIF polypeptides) which are capable of inducing NFκB. The present invention includes within its scope NFIF polypeptides, including NFIF-14b and NFIF-7a, DNA, including cDNA, encoding these polypeptides, and expression vectors capable of expressing NFIF polypeptides. Also included are methods and compositions for increasing NFκB induction in a patient, methods and compositions for lowering NFκB induction in a patient, methods for inhibiting inflammation, and methods for manufacutre of a medicament intended for the treatment and/or prevention of an NFκB-regulated inflammatory response. In addition, methods for determining whether a test compound inhibits or enhances the activity of NFIF polypeptides are provided. | 10-06-2011 |
| 20110230455 | AQUEOUS-BASED PHARMACEUTICAL COMPOSITION - An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucocillary forces which are present in the nasal cavity, a method of use of the composition and a method for preparation of the composition, including in preferred form the use of anti-inflammatory steroid, for example, triamcinoline acetonide, and an odorless form of the composition. | 09-22-2011 |
| 20100152427 | NUCLEIC ACID ENCODING A NOVEL DP RECEPTOR PROTEIN AND METHODS OF USE THEREOF - Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both. | 06-17-2010 |
| 20100143308 | AKT NUCLEIC ACIDS, POLYPEPTIDES, AND USES THEREOF - The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cell death associated with hypoxia, apoptosis or necrosis. | 06-10-2010 |
| 20100056514 | THIENOPYRAZOLES - Thienopyrazoles, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK). | 03-04-2010 |
| 20100028996 | RETROVIRAL VECTORS FOR DELIVERY OF INTERFERING RNA - Provided herein are retroviral vectors for delivering interfering RNA into cells. | 02-04-2010 |
| 20100021547 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS - The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient. | 01-28-2010 |
| 20090281147 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS - N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain. | 11-12-2009 |
| 20090275621 | 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF - The present invention is directed to 1,3,4-oxadiazalones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. | 11-05-2009 |
| 20090270458 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS - N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain. | 10-29-2009 |
| 20090247509 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands - The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D | 10-01-2009 |
| 20090209595 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS - N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain. | 08-20-2009 |
| 20090209594 | METHOD OF TREATING OF DEMYELINATING DISEASES OR CONDITIONS - N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain. | 08-20-2009 |
| 20090178151 | NUCLEIC ACID ENCODING A NOVEL PROSTAGLANDIN RECEPTOR PROTEIN AND METHODS OF USE THEREOF - Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both. | 07-09-2009 |
| 20090082340 | 3-SUBSTITUTED-5- AND 6-AMINOALKYL INDOLE-2-CARBOXYLIC ACID AMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I - The present invention discloses and claims methods for the treatment of a patient suffering from a disease or disorder ameliorated by inhibition of casein kinase Iε activity comprising the administration of a compounds of formula (I) and formula (II) | 03-26-2009 |
| 20080293090 | AUTOMATED SEMI-SOLID MATRIX ASSAY AND LIQUID HANDLER APPARATUS FOR THE SAME - An improved liquid handling machine capable of regulating the temperature of assay compounds in the automated preparation of culture trays for biological assays is disclosed. The machine includes a horizontally movable table positioned beneath a vertically movable head. The table is divided into a plurality of stations holding mixing trays, culture trays and reservoirs of liquid assay compound. The head holds a plurality of pipettes which aspirate and expel liquid to transfer and mix the assay compounds between the reservoir, the mixing trays and the culture trays upon coordinated movement of the head and the table as controlled by a microprocessor. Each station on the table has independent heating, cooling and temperature sensing elements for regulating the temperature of the liquid held in a tray or reservoir at the station. A device for automatically evaluating the results of the assay, such as by fluorescence, spectrophotometric or radioactive techniques is incorporated with the improved liquid handling machine. | 11-27-2008 |
| 20080287343 | METHOD FOR REDUCING CARDIOVASCULAR MORBIDITY AND MORTALITY IN PREDIABETIC PATIENTS AND PATIENTS WITH TYPE 2 DIABETES - This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient. | 11-20-2008 |
| 20080280784 | APPARATUS AND METHOD FOR USE IN SOLID PHASE CHEMICAL SYNTHESIS - An apparatus is disclosed for use in solid-phase chemical synthesis procedures. The apparatus allows the separation of a cleaved product from the solid-phase used to make the product, and subsequent removal of the solid-phase from the apparatus. The apparatus allows the cleaved product to be concentrated within the apparatus without transfer to another device. | 11-13-2008 |
| 20080255350 | SUBSTITUTED AZA-INDOLES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) - The present invention relates to a series of substituted aza-indole derivatives of the formula I: | 10-16-2008 |
| 20080227782 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS - This invention is directed to a compound of formula (I): | 09-18-2008 |
| 20080221078 | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia - The present invention discloses and claims a method of treating cognition deficits in a patient suffering from schizophrenia by administering to said patient a therapeutically effective amount of a CB1 receptor antagonist as described herein. In another aspect, this invention also discloses and claims a combination of one or more CB1 receptor antagonists and of one or more antipsychotic agents useful in the treatment of psychiatric disorders. The combination of this invention provides synergistic results in that the combination improves positive and negative symptoms of schizophrenia, weight gain and catalepsy. | 09-11-2008 |
| 20080200496 | SUBSTITUTED 1H-PYRROLO[3,2-b, 3,2-c, and 2,3-c]PYRIDINE-2-CARBOXAMIDES AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE Ie - The present invention discloses and claims compounds of formula (I) | 08-21-2008 |
